Founded in September 1999 and headquartered in Taipei, Taiwan, U-Vision Biotech Inc. currently employs 26 full-time employees with 70% of the manpower dedicated in research and development activities. The company’s mission is to combine knowledge and technologies in the fields of organic chemistry, genomics, proteomics, bioinformatics and biochip fabrication to speed up herbal drug leads discovery. Since the inception of the company, U-Vision’s growing research team has been committed to building up such a technology platform for phytocompounds identification and validation methodologies to fulfill its mission. 

By taking advantages of the several thousand years’ empirical experience from Traditional Chinese Medicines (TCM), U-Vision chose to target on those Taiwanese local herbs that have been known to be effective in treating complex diseases such as Type II Diabetes Mellitus and Breast Cancer, as well as curing simple but painful illness such as Wound Healing.

      Through the company’s innovative and ambitious approaches, U-Vision is on an aggressive track to become the market leader in identifying novel therapeutic targets. The company also provides consulting and research services in development of diagnostic marker hunting, microarray generation, and phytocompounds identification as well as their efficacious mechanism.

      Chinese Herbal Medicine has been well known for its unique effects in relieving complex diseases that refractory to western medication as well as simple illness or discomfort. But regrettably, the lack of reliable research data generated by methodologies of modern biological sciences and biotechnology have kept the precious property as an art for alternative choice rather than an innovation for pharmaceutical revolution. In U-Vision, we believe that exploration of the mechanisms of the herb’s therapeutic effects by using the modern platform technologies we have established will not only quickly revolutionize global pharmaceutical industry, but also greatly enhance the welfare of mankind at large.

Back